ADMA Biologics Inc (NASDAQ: ADMA) announced there would be a presentation on respiratory viral infections and its ASCENIV therapy. The FDA has approved ASCENIV, which is an intravenous immunoglobulin therapy. Moreover, Dr. Kevin Rosenbach will give the presentation. He will focus on a case where a patient with late-onset combined immunodeficiency struggled with struggled recurrent and chronic respiratory infections.
Other speakers at the event
Another speaker at the event will be Dr. Nolan Walter, who will discuss the unmet need, risk factors, and management of respiratory viral infections in primary immunodeficiency patients. Dr. Darren Siri will also be present for the event and will discuss immunoglobulin therapy management. The doctor will also talk about ASCENIV and its clinical profile. They will detail four patients with respiratory viral infections and other chronic conditions and how ASCENIV improved their health.
ASCENIV received FDA approval in 2019. The therapy treats primary immune deficiency syndrome, also called primary humoral immunodeficiency syndrome. This disease is common in people between 12 and 17.
The therapy uses the company’s plasma screening technology and a pooling design that combines plasma from typical sources with plasma from patients with respiratory viral syndrome.
ASCENIV has polyclonal antibodies. The body uses these proteins to neutralize microorganisms, including viruses and bacteria, and prevent disease infection. The patents that protect the product are 9,815,886, 9,714,283, and 9,107,906. ADMA Biologics has more information on the therapy on this website.
The company creates theories for immunodeficient people
ADMA Biologics, a pharmaceutical company, focuses on developing therapies for patients who are immunodeficient and have a higher risk of infectious diseases. The company has developed three therapies to treat immunodeficiencies. The Food and Drug Administration has approved these therapies.
The therapies include ASCENIV to treat primary immune deficiency syndrome. It has also developed BIVIGAM to treat PI. The third drug is NABI-HB which increases immunity against Hepatitis B.
The company has a plasma purification and fractionation faculty in Florida, where it develops its products. It also works through ADMA BioCenters, its subsidiary, to operate a plasma collector which exchanges its plasma for its products to be manufactured.
